Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.85 CAD | +1.61% | +2.59% | +0.73% |
23/04 | Big Pharma Split Corp. Declares April 2024 Distribution, Payable on May 9, 2024 | CI |
29/03 | Big Pharma Split Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 6.65M 4.86M 405M | Sales 2023 | 321K 234K 19.54M | Capitalization | 16.76M 12.25M 1.02B |
---|---|---|---|---|---|
Net income 2022 | 2M 1.46M 122M | Net income 2023 | - 0 0 | EV / Sales 2022 | 4.68 x |
Net Debt 2022 | 9.04M 6.6M 550M | Net Debt 2023 | 10.09M 7.38M 615M | EV / Sales 2023 | 83.7 x |
P/E ratio 2022 |
9.21
x | P/E ratio 2023 |
-25.9
x | Employees | - |
Yield 2022 |
8.49% | Yield 2023 |
9% | Free-Float | 0% |
1 day | +1.61% | ||
1 week | +2.59% | ||
Current month | +1.61% | ||
3 months | -3.69% | ||
6 months | +3.90% | ||
Current year | +0.73% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Kovacs
CEO | Chief Executive Officer | - | - |
Daniel Lazzer
DFI | Director of Finance/CFO | - | - |
Mary Medeiros
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kovacs
CEO | Chief Executive Officer | - | - |
Mary Medeiros
COO | Chief Operating Officer | - | - |
Nicholas Bontis
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
01/24/01 | 13.85 | +1.61% | 1,072 |
29/24/29 | 13.63 | 0.00% | 106 |
26/24/26 | 13.63 | +0.96% | 870 |
25/24/25 | 13.5 | 0.00% | 100 |
24/24/24 | 13.5 | +0.52% | 200 |
Delayed Quote Toronto S.E., May 02, 2024 at 12:31 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+0.73% | 11.76M | |
+3.16% | 229M | |
+24.04% | 206M | |
+16.41% | 186M | |
+9.71% | 111M | |
-0.32% | 82.73M | |
-14.81% | 50.95M |
- Stock Market
- Equities
- PRM Stock